Search

About us

Immunotech Biopharm Ltd: (stock code: 06978.HK, referred to as " Immunotech Biopharm ") is one of the earliest enterprises in China to conduct research on individualized cellular immunotherapy products in accordance with drug registration, and is one of the earliest new drugs enterprises to apply to the National Medical Products Administration for approval for clinical trials. It is the first cellular immunotherapy company in China to be successfully listed under Chapter 18A of the Listing Rules of the Hong Kong Stock Exchange.

...

News

Clinical Progress | Immunotech Biophara Ltd-B (06978. HK) aT19 Injection Successfully received an approval of Clinical Trial
Good News | Zhang Yonghua, Director of NGMC Product Department at Immunotech Biophara Ltd-B (06978. HK) , elected as "2023 Yizhuang Role Model"
FOUR ENTERPRISES HAVE BEEN AWARDED NATIONAL LEVEL DEMONSTRATION AWARDS IN BDA
A GOOD START! IMMUNOTECH BIOPHARA LTD (06978.HK) WAS SUCCESSFULLY SELECTED AS ONE OF THE 2023 KEY PRODUCT, PROCESS "ONE-STOP" APPLICATION DEMONSTRATION DIRECTIONS AND PROMOTION INSTITUTIONS
THE FIRST NATIONAL CONFERENCE OF INVESTIGATOR FOR THE PHASE II CLINICAL TRIAL OF IMMUNOTECH BIOPHARA LTD-B (06978.HK)  CAR-T-19 INJECTION WAS SUCCESSFULLY HELD
HEAVYWEIGHT AWARD | IMMUNOTECH BIOPHARA LTD-B(06978.HK) WON THE "GOLD AWARD"FOR THE TOP 10 INDUSTRIAL ENTERPRISES IN THE PHARMACEUTICAL SUPPIY CHAIN

Research

Patient

From November 2006 to April 2016, EAL® products have been used in clinical treatment of more than 4,000 patients in dozens of hospitals.

Recruitment

Address:8th Floor, Building 1, No. 1, Kangding Street, Beijing Economic and Technological Development Zone, Beijing
Resume delivery email:hr@eaal.net
Contact numbe:010-88400295

 

Copyright: Immunotech Applied Science Limited   京ICP备19008112号-1